Please use this identifier to cite or link to this item:
|Title:||Anti-platelet and tissue engineering approaches to biomaterial blood compatibilization : how well have these been translated into the clinic?||Authors:||Irvine, Scott Alexander.
Venkatraman, Subbu S.
|Issue Date:||2012||Source:||Irvine, S. A., Yun, X., & Venkatraman, S. (2012). Anti-platelet and tissue engineering approaches to biomaterial blood compatibilization: how well have these been translated into the clinic?. Drug Delivery and Translational Research, 2(5), 384-397.||Series/Report no.:||Drug delivery and translational research||Abstract:||In this article, we provide an update on the various approaches to “blood compatibilization”, and include both passive and active approaches to compatibilizing biomaterials in contact with blood. Broadly speaking, the surface modification approaches involved either repel platelets or attract endothelial cells. For platelet-repelling surfaces, heparin immobilization seems to be the most successful approach. At least two such surfaces have been approved by the health authorities in various countries for applications involving short-term contact with blood. For active endothelialization, ex vivo seeding with autologous cells has been translated into the clinic, while selective endothelial cell capture is a promising approach. In spite of over 30 years of research in this area, a truly intrinsically non-clotting surface has not been developed yet; certain promising avenues have been indicated by the research, which we will critically assess here.||URI:||https://hdl.handle.net/10356/95863
|ISSN:||2190-393X||DOI:||10.1007/s13346-012-0077-z||Rights:||© 2012 Controlled Release Society.||Fulltext Permission:||none||Fulltext Availability:||No Fulltext|
|Appears in Collections:||MSE Journal Articles|
Updated on Jun 18, 2020
Updated on Mar 4, 2021
Page view(s) 20444
Updated on Apr 16, 2021
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.